Silence Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silence Therapeutics Plc on August 12, 2026, covering events occurring on August 10 and August 11, 2026. The Company, incorporated in England and Wales, is engaged in the development of RNA interference therapeutics. The filing primarily reports the entry into a material definitive agreement for an underwritten public offering of American Depositary Shares (ADSs).
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than operational financial results. Key metrics regarding the offering include:
- Shares Issued: 12,962,963 ADSs (each representing three ordinary shares).
- Offering Price: $13.50 per ADS to the public.
- Underwriting Price: $12.69 per ADS.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,944,444 ADSs.
- Estimated Net Proceeds: Approximately $164.0 million, or approximately $188.7 million if the over-allotment option is exercised in full.
- Underwriters: Jefferies LLC and Morgan Stanley & Co. LLC.
The filing text does not provide current revenue, profit, cash flow, margins, or debt levels; these operational metrics are not the subject of this specific 8-K filing.
Material Changes
The primary material change is the execution of the Underwriting Agreement on August 11, 2026, and the commencement of the public offering. This represents a significant increase in the Company's equity capital and cash liquidity upon closing, which is expected to occur on August 13, 2026.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the completion of the Offering and the net proceeds. Management notes that actual results may differ materially due to risks described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. The Company disclaims any obligation to update these forward-looking statements except as required by law. No specific operational guidance or clinical trial updates are provided in this document.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on or after August 13, 2026.
- Confirm whether the underwriters exercised the over-allotment option for the additional 1,944,444 ADSs.
- Review the Company's most recent Form 10-K (filed March 5, 2026) for current cash burn rates and liquidity position prior to this capital raise.
- Check subsequent filings for any changes in the use of proceeds or updates to the Company's clinical development pipeline.